Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,esgPopulated,tradeable,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,shortName,exchange,trailingAnnualDividendRate,trailingAnnualDividendYield,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GNNSF,861569000,2077980032,73975000,,-61926500,-86114000,-45926500,60129000,73860000,-60244000,-60244000,,,,,,-1469500,112226000,172470000,38366000,-1682500,,-60457000,-45926500,26020000,1066547000,631815000,901705000,142905000,1447406000,1954000,20877000,-175006000,296131000,14116000,8210000,20876000,629058000,327911000,3702000,581000,24922000,379232000,993174000,13988000,136245000,165707000,1260000,31745000,23376000,26160500.0,4252500.0,-7515000.0,-4000500.0,-6028500.0,44289500.0,-38817500.0,-16260500.0,2337000.0,-27611000.0,9139500.0,-96000.0,-5392500.0,-38619000.0,14232500.0,4363500.0,-31869000.0,,665263000,en-US,US,EQUITY,False,Delayed Quote,0.0,4.83 - 4.83,4.83,0.0,0.0,0,0,finmb_318952834,Other OTC,Genscript Biotech Corporation,USD,432,52,3.53,2.7153847,1.3 - 5.3,-0.47000027,-0.08867929,1.3,5.3,USD,False,False,us_market,4.83,1630091015,0.0,4.83,4.83,4.83,1,PREPRE,GENSCRIPT BIOTECH CORPORATION,PNK,0.002,0.0004140787,-0.108,0,0.462,4.4589777,0.37102222,0.08320791,3.153262,1.676738,0.53174716,10036643840,10.454545,15,America/New_York,EDT,-14400000,4,1.49,,,5.3,1.3,4.459,3.1533,432,52,2.08B,,1.03B,39.07%,15.49%,,,,,,,,0.00,0.04%,,0.00%,,"Jun 04, 2017",,,"Dec 30, 2020","Dec 30, 2020",-52.44%,-52.50%,-10.98%,-47.38%,390.85M,0.21,48.20%,255.89M,-175.35M,-204.94M,-0.1080,,771.17M,0.4,55M,6.74,3.03,0.46,-151.09M,-225.88M,Value,211122,Healthcare,4592,"Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",Nanjing,86 25 5889 7288,1609372800,China,http://www.genscript.com,86400,Jiangning Science Park,Biotechnology,"No. 28, Yongxi Road"
t-1,GNNSF,861569000,2077980032,73975000,,-61926500,-86114000,-45926500,60129000,73860000,-60244000,-60244000,,,,,,-1469500,112226000,172470000,38366000,-1682500,,-60457000,-45926500,26020000,1066547000,631815000,901705000,142905000,1447406000,1954000,20877000,-175006000,296131000,14116000,8210000,20876000,629058000,327911000,3702000,581000,24922000,379232000,993174000,13988000,136245000,165707000,1260000,31745000,23376000,26160500.0,4252500.0,-7515000.0,-4000500.0,-6028500.0,44289500.0,-38817500.0,-16260500.0,2337000.0,-27611000.0,9139500.0,-96000.0,-5392500.0,-38619000.0,14232500.0,4363500.0,-31869000.0,,665263000,en-US,US,EQUITY,False,Delayed Quote,0.0,4.83 - 4.83,4.83,0.0,0.0,0,0,finmb_318952834,Other OTC,Genscript Biotech Corporation,USD,432,52,3.53,2.7153847,1.3 - 5.3,-0.47000027,-0.08867929,1.3,5.3,USD,False,False,us_market,4.83,1630091015,0.0,4.83,4.83,4.83,1,PREPRE,GENSCRIPT BIOTECH CORPORATION,PNK,0.002,0.0004140787,-0.108,0,0.462,4.4589777,0.37102222,0.08320791,3.153262,1.676738,0.53174716,10036643840,10.454545,15,America/New_York,EDT,-14400000,4,1.49,,,5.3,1.3,4.459,3.1533,432,52,2.08B,,1.03B,39.07%,15.49%,,,,,,,,0.00,0.04%,,0.00%,,"Jun 04, 2017",,,"Dec 30, 2020","Dec 30, 2020",-52.44%,-52.50%,-10.98%,-47.38%,390.85M,0.21,48.20%,255.89M,-175.35M,-204.94M,-0.1080,,771.17M,0.4,55M,6.74,3.03,0.46,-151.09M,-225.88M,Value,211122,Healthcare,4592,"Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",Nanjing,86 25 5889 7288,1609372800,China,http://www.genscript.com,86400,Jiangning Science Park,Biotechnology,"No. 28, Yongxi Road"
t-2,GNNSF,900802000,2077980032,57725500,,-79023500,-57910000,-56546000,38712000,54086500,-42351000,-42351000,,-2255000.0,,,,1231000,83197000,125548000,29110500,-36672500,,-80254500,-56546000,27352000,1050710000,554357000,943361000,133244000,1439808000,1918000,40892000,-83153000,268078000,15207000,-26114000,17357000,706693000,278686000,3949000,558000,-8880000,312177000,1059643000,8072000,173050000,65400000,1487000,24179000,22733000,-12917000.0,2445500.0,-42568000.0,15163500.0,318130000.0,-16791000.0,227148000.0,-4730000.0,-478500.0,-47935500.0,7026000.0,615000.0,-2090000.0,3664500.0,-18569500.0,14355500.0,-29070500.0,246041000.0,780957000,en-US,US,EQUITY,False,Delayed Quote,0.0,4.83 - 4.83,4.83,0.0,0.0,0,0,finmb_318952834,Other OTC,Genscript Biotech Corporation,USD,432,52,3.53,2.7153847,1.3 - 5.3,-0.47000027,-0.08867929,1.3,5.3,USD,False,False,us_market,4.83,1630091015,0.0,4.83,4.83,4.83,1,PREPRE,GENSCRIPT BIOTECH CORPORATION,PNK,0.002,0.0004140787,-0.108,0,0.462,4.4589777,0.37102222,0.08320791,3.153262,1.676738,0.53174716,10036643840,10.454545,15,America/New_York,EDT,-14400000,4,1.49,,,5.3,1.3,4.459,3.1533,432,52,2.08B,,1.03B,39.07%,15.49%,,,,,,,,0.00,0.04%,,0.00%,,"Jun 04, 2017",,,"Dec 30, 2020","Dec 30, 2020",-52.44%,-52.50%,-10.98%,-47.38%,390.85M,0.21,48.20%,255.89M,-175.35M,-204.94M,-0.1080,,771.17M,0.4,55M,6.74,3.03,0.46,-151.09M,-225.88M,Value,211122,Healthcare,4592,"Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",Nanjing,86 25 5889 7288,1609372800,China,http://www.genscript.com,86400,Jiangning Science Park,Biotechnology,"No. 28, Yongxi Road"
t-3,GNNSF,900802000,2077980032,57725500,,-79023500,-57910000,-56546000,38712000,54086500,-42351000,-42351000,,-2255000.0,,,,1231000,83197000,125548000,29110500,-36672500,,-80254500,-56546000,27352000,1050710000,554357000,943361000,133244000,1439808000,1918000,40892000,-83153000,268078000,15207000,-26114000,17357000,706693000,278686000,3949000,558000,-8880000,312177000,1059643000,8072000,173050000,65400000,1487000,24179000,22733000,-12917000.0,2445500.0,-42568000.0,15163500.0,318130000.0,-16791000.0,227148000.0,-4730000.0,-478500.0,-47935500.0,7026000.0,615000.0,-2090000.0,3664500.0,-18569500.0,14355500.0,-29070500.0,246041000.0,780957000,en-US,US,EQUITY,False,Delayed Quote,0.0,4.83 - 4.83,4.83,0.0,0.0,0,0,finmb_318952834,Other OTC,Genscript Biotech Corporation,USD,432,52,3.53,2.7153847,1.3 - 5.3,-0.47000027,-0.08867929,1.3,5.3,USD,False,False,us_market,4.83,1630091015,0.0,4.83,4.83,4.83,1,PREPRE,GENSCRIPT BIOTECH CORPORATION,PNK,0.002,0.0004140787,-0.108,0,0.462,4.4589777,0.37102222,0.08320791,3.153262,1.676738,0.53174716,10036643840,10.454545,15,America/New_York,EDT,-14400000,4,1.49,,,5.3,1.3,4.459,3.1533,432,52,2.08B,,1.03B,39.07%,15.49%,,,,,,,,0.00,0.04%,,0.00%,,"Jun 04, 2017",,,"Dec 30, 2020","Dec 30, 2020",-52.44%,-52.50%,-10.98%,-47.38%,390.85M,0.21,48.20%,255.89M,-175.35M,-204.94M,-0.1080,,771.17M,0.4,55M,6.74,3.03,0.46,-151.09M,-225.88M,Value,211122,Healthcare,4592,"Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",Nanjing,86 25 5889 7288,1609372800,China,http://www.genscript.com,86400,Jiangning Science Park,Biotechnology,"No. 28, Yongxi Road"
